# US 2019/0376080 A1 · Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376080 A1
- Document ID: US20190376080A1
- Status: Published application
- Kind: A1
- Application number: 16/398,691
- Filed: 2019-04-30
- Published: 2019-12-12
- Earliest claimed: 2012-02-02
- Assignees: Baylor College of Medicine
- Applicants: Baylor College of Medicine
- Inventors: Brendan LEE; Kilian GUSE; Zhechao RUAN
- Web page: https://patentgrep.com/patent/US20190376080A1

## CPC

- C12N 15/86: Viral vectors
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07K 14/545: IL-1
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10071: Demonstrated in vivo effect
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10371: Demonstrated in vivo effect
- C12N 2800/24: Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-I receptor antagonist (II-1 Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-I receptor antagonist (II-I Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-I receptor antagonist (II-I Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.

## Claims

### Claim 1

An adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (Il-1 Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1 Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (Il-1 Ra) gene within synovial cells is regulated by an inflammation-inducible promoter, which is located upstream of the reading frame of the nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1 Ra) and which is specifically activated by increased levels of immune stimulatory substances.

### Claim 2 (depends on 1)

The adenoviral-based biological delivery and expression system according to claim 1, wherein the inflammation-inducible promoter is selected from the group consisting of NF-1κ13 promoter, interleukin 6 (Il-6) promoter, interleukin-1 (Il-1) promoter, tumor necrosis factor (TNF) promoter, cyclooxygenase 2 (COX-2) promoter, complement factor 3 (C3) promoter, serum amyloid A3 (SAA3) promoter, macrophage inflammatory protein-1a (MlP-1 α) promoter, or hybrid constructs of the above.

### Claim 3 (depends on 1)

The adenoviral-based biological delivery and expression system according to claim 1, wherein the helper-dependent adenoviral vector comprises a nucleic acid sequence set forth in SEQ ID NO 2 or SEQ ID NO 3, or a biologically effective part thereof.

### Claim 4 (depends on 1)

The adenoviral-based biological delivery and expression system according to claim 1, wherein the mammalian interleukin-1 receptor antagonist (Il-1 Ra) is selected from the group consisting of murine Il-1 Ra, equine Il-1 Ra, canine Il-1 Ra, cat Il-1 Ra, rabbit Il-1 Ra, hamster Il-1 Ra, bovine Il-1Ra, camel Il-1 Ra or their homologs in other mammalian species.

### Claim 5 (depends on 1)

The adenoviral-based biological delivery and expression system according to claim 1, wherein the helper-dependent adenoviral vector further comprises a marker gene that allows monitoring of the vector genome in the synovial cells.

### Claim 6 (depends on 1)

The adenoviral-based biological delivery and expression system according to claim 1, wherein the helper-dependent vector comprises a nucleic acid sequence set forth in SEQ ID NO 1 or a conserved sequence thereof encoding for the same amino acids.

### Claim 7 (depends on 1)

The adenoviral-based biological delivery and expression system according to claim 1, wherein the helper-dependent vector has at least 50%, 60%, 80%, 90% sequence homology with the nucleic acid sequence set forth in SEQ ID NO 1.

### Claim 8

A pharmaceutical composition, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1 Ra), left and right inverted terminal repeats (L ITR and R ITR), an adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (Il-1 Ra) gene within synovial cells is regulated by an inflammation-inducible promoter, which is located upstream of the reading frame of the nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1 Ra) and which is specifically activated by increased levels of immune stimulatory substances, for the treatment or prevention of osteoathritis.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the inflammation-inducible promoter is selected from the group consisting of NF-KB promoter, interleukin 6 (11-6) promoter, interleukin-1 (11-1) promoter, tumor necrosis factor (TNF) promoter, cyclooxygenase 2 (COX-2) promoter, complement factor 3 (C3) promoter, serum amyloid A3 (SAA3) promoter, macrophage inflammatory protein-1a (MIP-1a) promoter, or hybrid constructs of the above.

### Claim 10 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the helper-dependent adenoviral vector comprises a nucleic acid sequence set forth in SEQ ID NO 2 or SEQ ID NO 3, or a biologically effective part thereof.

### Claim 11 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the mammalian interleukin-1 receptor antagonist (Il-1 Ra) is selected from the group consisting of murine Il-1 Ra, equine Il-1 Ra, canine Il-1 Ra, cat Il-1 Ra, rabbit Il-1 Ra, hamster Il-1 Ra, bovine Il-1 Ra, camel Il-1 Ra or their homologs in other mammalian species.

### Claim 12 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the helper-dependent adenoviral vector further comprises a marker gene that allows monitoring of the vector genome in the synovial cells.

### Claim 13 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the helper-dependent vector comprises a nucleic acid sequence set forth in SEQ ID NO 1 or a conserved sequence thereof encoding for the same amino acids.

### Claim 14 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the helper-dependent vector has at least 50%, 60%, 80%, 90% sequence homology with the nucleic acid sequence set forth in SEQ ID NO 1.

### Claim 15 (depends on 1)

Use of an adenoviral-based biological delivery and expression system according to claim 1 for expressing interleukin-1 receptor antagonist (Il-1 Ra) in synovial cells ex vivo.
